SAN DIEGO, Sept. 27, 2017 /PRNewswire/ -- Shareholder Rights
Law Firm Johnson Fistel, LLP, is investigating potential violations
of federal and state laws by certain officers and directors of PTC
Therapeutics, Inc. (NASDAQ: PTCT) ("PTC " or "PTC Therapeutics").
On August 28, 2017, a federal court
denied in part a motion to dismiss a securities fraud class action
filed against PTC and certain of its officers and directors. PTC a
biopharmaceutical company focuses on the discovery, development,
and commercialization of orally administered, small molecule drugs
that target post-transcriptional control processes.
The class action complaint alleges that, defendants throughout
the Class Period issued materially false and misleading statements
to investors and/or failed to disclose that: (1) PTC Therapeutics'
NDA for Translarna that it submitted to the FDA was not
sufficiently complete to permit a substantive review of the
application; (2), as such, the application would not be reviewed
nor approved by the FDA; (3) the impending non-approval of the NDA
would have a negative material impact on PTC Therapeutics'
operations and prospects; and (4) as a result, PTC Therapeutics'
financial statements were materially false and misleading at all
relevant times. When the true details entered the market, the
lawsuit claims that investors suffered damages.
If you have held PTC shares continuously since at
least November 20l4, you may have standing to hold the Company
harmless from the damage the officers or directors are alleged to
have caused the Company. You may also be able to assist
in reforming the Company's corporate governance to prevent future
wrongdoing.
If you are a PTC shareholder, continuously since at least
November 20l4, and are interested in learning more about the
investigation or your legal rights and remedies, please contact
lead analyst Jim Baker
(jimb@johnsonfistel.com) at 619-814-4471. If you email, please
include your phone number.
About Johnson Fistel,
LLP:
Johnson Fistel, LLP is a nationally
recognized shareholder rights law firm with offices in California, New
York and Georgia. The firm
represents individual and institutional investors in shareholder
derivative and securities class action lawsuits. For more
information about the firm and its attorneys, please visit
http://www.johnsonfistel.com. Attorney advertising. Past results do
not guarantee future outcomes.
Contact:
Johnson Fistel, LLP
Jim Baker, 619-814-4471
jimb@johnsonfistel.com
View original
content:http://www.prnewswire.com/news-releases/long-term-ptc-investors-johnson-fistel-initiates-investigation-of-ptc-therapeutics-inc-encourages-investors-to-contact-the-firm-300526684.html
SOURCE Johnson Fistel, LLP